Dosage form comprising a polymeric matrix

2:

• The dosage form according to claim 1, wherein the monomers (a) comprise 2-ethylhexyl methacrylate (EHMA) and ethyl methacrylate (EMA), or 2-ethylhexyl methacrylate (EHMA) and methyl methacrylate (MMA), at a ratio by weight from 5:1 to 1:1.

3:

• The dosage form according to claim 1, wherein the monomers (b) are selected from the group consisting of 2 hydroxyethyl methacrylate (HEMA), 2-hydroxypropyl methacrylate, 3-hydroxypropyl methacrylate, 2,3-dihydroxy propyl methacrylate, 2 hydroxyethyl acrylate, 2-hydroxypropyl acrylate, 3-hydroxy propyl acrylate, 2,3-dihydroxypropyl acrylate, and any mixtures thereof.

4:

• The dosage form according to claim 1, wherein the monomers (c) comprises 2-trimethylammonium ethyl methacrylate Chloride (TMAEMC), 2-trimethylammonium propyl methacrylate chloride (TMAPMC), or both.

6:

• The dosage form according to claim 1, wherein the one or more polymer(s) have a minimum film forming temperature (MFFT) of 35° C. or lower.

7:

• The dosage form according to claim 1, wherein the one or more polymer(s) have a midpoint glass transition temperature (Tmg) in a range from 0 to 50° C.

8:

• The dosage form according to claim 1, wherein the one or more polymer(s) have a weight average molecular weight Mw from 10,000 to 200,000 Dalton.

9:

• The dosage form according to claim 1, wherein the polymeric matrix comprises 10 to 99% by weight of the one or more polymer(s), 1 to 90% by weight of the biologically active ingredient, and 0 to 89% by weight of pharmaceutically or nutraceutically acceptable excipients.

10:

• The dosage form according to claim 9, wherein the pharmaceutically or nutraceutically acceptable excipients are selected from the group consisting of antioxidants, brighteners, binding agents, flavoring agents, flow aids, glidants, penetration-promoting agents, pigments, plasticizers, further polymers, pore-forming agents, stabilizers and any combinations thereof.

11:

• The dosage form according to claim 1, which is an orally delivered medicament with resistance against an influence of ethanol.

(canceled)

14:

• The dosage form according to claim 4, wherein the monomers (c) comprise 2-trimethylammonium ethyl methacrylate chloride (TMAEMC).